Abstract
One of the major goals for the immunotherapy of autoimmune diseases is the induction
of regulatory T cells that mediate immunologic tolerance. Parenteral administration
of anti-CD3 monoclonal antibody is an approved therapy for transplantation in humans
and is effective in autoimmune diabetes. We have found that oral administration of
anti-CD3 monoclonal antibody is biologically active in the gut and suppresses experimental
autoimmune encephalomyelitis both prior to disease induction and at the height of
disease. Oral anti-CD3 antibody acts by inducing a unique type of regulatory T cell
characterized by latency-associated peptide (LAP) on its cell surface that functions
in vivo and in vitro via TGF-β dependent mechanism. Orally delivered antibody would not have side effects
including cytokine release syndromes, thus oral anti-CD3 antibody is clinically applicable
for chronic therapy. These findings identify a novel and powerful immunologic approach
that is widely applicable for the treatment of human autoimmune conditions.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of the Neurological SciencesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Acquisition of immunologic self-tolerance.Cell. 1989; 57: 1073-1081
- Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody.Diabetes. 1992; 41: 385-391
- Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice.Proc Natl Acad Sci U S A. 1994; 91: 123-127
- CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice.J Immunol. 1997; 158: 2947-2954
- Remission and pancreas isograft survival in recent onset diabetic NOD mice after treatment with low-dose anti-CD3 monoclonal antibodies.Transpl Immunol. 2002; 10: 63-72
- Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance.J Immunol. 2002; 168: 933-941
- TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes.Nat Med. 2003; 9: 1202-1208
- Reversal of experimental allergic encephalomyelitis with non-mitogenic, non-depleting anti-CD3 mAb therapy with a preferential effect on T(h)1 cells that is augmented by IL-4.Int Immunol. 2001; 13: 1109-1120
- Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis.J Immunol. 2005; 174: 4525-4534
- Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.N Engl J Med. 2002; 346: 1692-1698
- Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).J Clin Invest. 2003; 111: 409-418
- A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.Diabetes. 2005; 54: 1763-1769
- Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.N Engl J Med. 2005; 352: 2598-2608
- Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial.J Rheumatol. 2002; 29: 1907-1913
- Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody.Eur J Immunol. 1982; 12: 979-982
- Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3.J Immunol. 1986; 137: 830-838
- Anti-CD3 antibodies: towards clinical antigen-specific immunomodulation.Curr Opin Pharmacol. 2004; 4: 403-407
- CD3-specific antibodies as promising tools to aim at immune tolerance in the clinic.Int Rev Immunol. 2006; 25: 215-233
- CD3-specific antibody-induced active tolerance: from bench to bedside.Nat Rev Immunol. 2003; 3: 123-132
- CD3-specific antibodies: a portal to the treatment of autoimmunity.Nat Rev Immunol. 2007; 7: 622-632
- CD3-specific antibodies restore self-tolerance: mechanisms and clinical applications.Curr Opin Immunol. 2005; 17: 632-637
- Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis.Science. 1994; 265: 1237-1240
- Activation of CD25(+)CD4(+) regulatory T cells by oral antigen administration.J Immunol. 2001; 167: 4245-4253
- Induction of immunity and oral tolerance with polymorphic class II major histocompatibility complex allopeptides in the rat.Proc Natl Acad Sci U S A. 1992; 89: 7762-7766
- Epitopes of myelin basic protein that trigger TGF-beta release after oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven bystander suppression.J Immunol. 1993; 151: 7307-7315
- Regulatory Th2-type T cell lines against insulin and GAD peptides derived from orally- and nasally-treated NOD mice suppress diabetes.J Autoimmun. 1999; 12: 251-258
- IL-4 is a differentiation factor for transforming growth factor-beta secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis.Eur J Immunol. 1998; 28: 2780-2790
- Mucosal administration of IL-10 enhances oral tolerance in autoimmune encephalomyelitis and diabetes.Int Immunol. 2001; 13: 825-833
- Induction of specific tolerance to allografts in rats by therapy with non-mitogenic, non-depleting anti-CD3 monoclonal antibody: association with TH2 cytokines not anergy.Transplantation. 1999; 67: 605-613
- Monoclonal antibodies defining distinctive human T cell surface antigens.Science. 1979; 206: 347-349
- Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts.N Engl J Med. 1981; 305: 308-314
- Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells.J Immunol. 1989; 142: 737-743
- OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties.J Immunol. 1980; 124: 2708-2713
- Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation.Eur J Immunol. 1990; 20: 509-515
- Hypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice: role of tumor necrosis factor.Eur J Immunol. 1990; 20: 707-710
- Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome-dosage and kinetics prerequisites.Transplantation. 1991; 51: 334-338
- The anti-CD3-induced syndrome: a consequence of massive in vivo cell activation.Curr Top Microbiol Immunol. 1991; 174: 121-134
- Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients.Transplantation. 1989; 47: 606-608
- Induction of T cell proliferation with anti-CD3 switch-variant monoclonal antibodies: effects of heavy chain isotype in monocyte-dependent systems.Eur J Immunol. 1987; 17: 1599-1604
- Anti-CD3 F(ab′)2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb.Transplantation. 1990; 49: 1117-1123
- In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants.J Clin Invest. 1994; 93: 2519-2525
- The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties.Eur J Immunol. 1993; 23: 403-411
- Induction of T helper cell hyporesponsiveness in an experimental model of autoimmunity by using nonmitogenic anti-CD3 monoclonal antibody.J Immunol. 1994; 153: 3319-3325
- A non-activating “humanized” anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo.Transplantation. 1994; 57: 1537-1543
- Use of anti-CD3 epsilon F(ab′)2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation.J Immunol. 1995; 154: 5542-5554
- Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy.J Exp Med. 1997; 185: 1413-1422
- Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets.J Immunol. 1998; 160: 4841-4849
- TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs.J Clin Invest. 2005; 115: 2904-2913
- Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection.Transplantation. 1999; 68: 1632-1637
- Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection.Transplantation. 1999; 68: 608-616
- Induction of long-term specific tolerance to allografts in rats by therapy with an anti-CD3-like monoclonal antibody.Transplantation. 1993; 55: 459-468
- Anti-CD3 epsilon F(ab′)2 fragments inhibit T cell expansion in vivo during graft-versus-host disease or the primary immune response to nominal antigen.J Immunol. 1997; 159: 5821-5833
- In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.J Immunol. 1994; 152: 3665-3674
- Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+CD25−LAP+ T cells.Nat Med. 2006; 12: 627-635
- An open trial of OKT3 in patients with multiple sclerosis.Neurology. 1991; 41: 1047-1052
- CD4+CD25− T cells that express latency-associated peptide on the surface suppress CD4+CD45RBhigh-induced colitis by a TGF-beta-dependent mechanism.J Immunol. 2003; 170: 2516-2522
- Recovery from experimental allergic encephalomyelitis is TGF-beta dependent and associated with increases in CD4+LAP+ and CD4+CD25+ T cells.Int Immunol. 2006; 18: 495-503
- Induction of anergy or active suppression following oral tolerance is determined by antigen dosage.Proc Natl Acad Sci U S A. 1994; 91: 6688-6692
- Peripheral deletion of antigen-reactive T cells in oral tolerance.Nature. 1995; 376: 177-180
- Th3 cells in peripheral tolerance. I. Induction of Foxp3-positive regulatory T cells by Th3 cells derived from TGF-beta T cell-transgenic mice.J Immunol. 2007; 178: 179-185
- Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody.Diabetes. 2007; 56: 2103-2109
Wu HF, Quintana F, Weiner HL. Nasal anti-CD3 antibody ameliorates lupus by inducing an IL-10 secreting CD4+CD25-LAP+regulatory T cell and is associated with downregulation of IL-17+CD4+ICOS+CXCR5+ follicular helper T cells. J Immunol in press.
- Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli.N Engl J Med. 1988; 318: 1240-1243
- Inflammation and insulin resistance.J Clin Invest. 2006; 116: 1793-1801
Article info
Publication history
Accepted:
July 24,
2008
Received in revised form:
July 10,
2008
Received:
March 13,
2008
Identification
Copyright
© 2008 Elsevier B.V. Published by Elsevier Inc. All rights reserved.
